<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://faron.com/wp-sitemap.xsl" ?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://faron.com/releases-and-publications/farons-financial-calendar-for-2025/</loc><lastmod>2025-01-30T18:40:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-presents-bexmab-data-at-ash-annual-meeting/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/interactions-with-uk-regulatory-authorities/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/positive-phase-2-interim-results-from-bexmab-trial/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/targeting-soluble-clever-1-for-autoimmune-diseases/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/shareholders-nomination-board/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-capital-markets-day-2024/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-capital-markets-day/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options/</loc><lastmod>2025-01-29T15:41:51+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-2024-half-year-financial-results/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-grants-fast-track-designation-for-bexmarilimab/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-half-year-financial-results/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-research-collaboration-and-dod-grant/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/appointment-of-chief-financial-officer/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-2/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-appoints-dr-petri-bono-as-new-cmo/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-positive-fda-feedback/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-settlement/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-replacement/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company/</loc><lastmod>2025-01-29T15:41:52+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-2/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-3/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-4/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/new-shares-registered-with-finnish-trade-register/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fully-subscribed-eur-30-7-million-share-offering/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-rex-retail-offer/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-commences-a-share-offering/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/initial-positive-data-from-phase-2-of-bexmab/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/issuance-of-warrants/</loc><lastmod>2025-01-29T15:41:54+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/founders-named-european-inventor-award-finalists/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/replacement-board-change/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-financial-status/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/board-change/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-confirms-plans-under-new-leadership/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/appointment-of-chief-financial-officer-2/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/approval-of-warrant-terms-and-conditions/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/decisions-of-the-board-of-directors/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/appointment-of-chief-executive-officer/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-the-annual-general-meeting/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/announcement-of-placing/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/issue-of-warrants-to-ipf-funding-update/</loc><lastmod>2025-01-29T15:41:55+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-annual-report-2023/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/additional-positive-data-from-phase-1-of-bexmab/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-host-bexmab-webcast/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-annual-general-meeting-2024/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/financial-statement-january-1-to-december-31-2023/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/binding-commitments-for-convertible-loans/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/replacement-update-to-2024-financial-calendar/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-to-farons-financial-calendar-for-2024/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/continued-negotiations-regarding-events-of-default/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/events-of-default/</loc><lastmod>2025-01-29T15:41:56+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/further-re-exercise-of-options/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmab-insights-into-patient-profiles/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-first-hma-failed-mds-patient-dosed-with-bexmarilimab-as-part-of-phase-2-of-bexmab-trial/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-financial-calendar-for-2024/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/phase-1-bexmab-data-presented-at-ash/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-trial-in-cell-reports-medicine/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-3/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-initiates-phase-2-part-of-bexmab-study/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-data-from-bexmab-study-at-ash/</loc><lastmod>2025-01-29T15:41:57+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/managers-transactions/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-2/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-issue-and-placing/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-positive-bexmab-study-update/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-host-webcast-on-new-bexmab-study-data/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/board-changes/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-egm/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-appoints-interim-chief-medical-officer/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/change-in-the-board-of-directors/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-ltd-to-present-at-the-h-c-wainwright-25th-annual-global-investment-conference/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-faron-pharmaceuticals-ltds-extraordinary-general-meeting/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-directors-dealing-issue-of-equity/</loc><lastmod>2025-01-29T15:41:58+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-2023-half-year-financial-results/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-orphan-drug-designation-for-bexmarilimab/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-half-year-financial-results-2/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-participate-at-canaccord-conference/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-4/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-hold-bexmab-study-conference-call/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmab-study-update/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-5/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/announcement-of-placing-2/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-3/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/new-biomarker-data-from-bexmab-study-at-eha2023/</loc><lastmod>2025-01-29T15:41:59+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/board-member-to-assume-transactional-advisor-role/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-efficacy-and-safety-in-matins-trial/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-kol-event/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/poster-presentations-at-aacr-2023/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmab-study-update-2/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-at-canaccord-oncology-virtual-conference/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/appointment-of-chief-financial-officer-3/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/board-change-2/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-agm/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/positive-fda-feedback-to-progress-bexmarilimab/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-faron-pharmaceuticals-ltds-agm/</loc><lastmod>2025-01-29T15:42:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-annual-report-2022-published/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/financial-statement-january-1-to-december-31-2022/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-to-farons-financial-calendar-for-2023/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-2022-full-year-results-and-annual-report/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-6/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-7/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing-2/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-issue-and-placing-2/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmab-study-update-3/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-financial-calendar-for-2023/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmab-study-update-4/</loc><lastmod>2025-01-29T15:42:01+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-appoints-maija-hollmen-phd-as-cso/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/amendment-terms-and-conditions-with-ipf-partners/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-poster-presentation-at-sitc/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmab-study-update-5/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-8/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-9/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-presents-results-from-pd-1-blockade-refractory-melanoma-cohort-of-matins-trial-at-19th-international-congress-of-the-society-for-melanoma-research/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing-3/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-issue-and-placing-of-shares/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-5/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/top-line-data-on-bexmarilimab-dose-variation/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-host-bexmarilimab-update-webcast/</loc><lastmod>2025-01-29T15:42:02+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-data-presented-at-mhsr-symposium/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-upcoming-conferences/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-reports-2022-half-year-financial-results/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-half-year-financial-results-3/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-egm-2/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-10/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/registration-of-new-shares/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/announcement-of-placing-3/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-notice-of-egm/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-top-line-12-month-survival-results/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-patient-dosed-in-ph-i-ii-bexmab-combo-study/</loc><lastmod>2025-01-29T15:42:03+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-4/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/presentation-of-biomarker-analysis-at-asco/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-us-food-and-drug-administration-and-finnish-medicines-agency-approval-to-initiate-phase-i-ii-bexmarilimab-combination-study-in-hematologic-malignancies/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/ex-vivo-data-presented-at-eha2022-congress/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/mol-cancer-ther-publishes-bexmarilimab-research/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-6/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/board-changes-2/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-the-agm/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-presents-results-from-melanoma-cohort-of-matins-trial-at-18th-congress-of-the-european-association-of-dermato-oncology-eado/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/managers-transactions-2/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-closes-hibiscus-trial/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-faron-pharmaceuticals-ltds-agm-2/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-annual-report-2021-published/</loc><lastmod>2025-01-29T15:42:04+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/financial-statement-january-1-to-december-31-2021/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-publishes-research-from-interest-trial/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/presentation-of-biomarker-data-at-aacr-2022/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-2021-full-year-results-and-annual-report/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-upcoming-conferences-2/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-board-issues-warrants-to-ipf-partners/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-obtains-debt-funding-from-ipf-partners/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-updates-on-bexmarilimab-development-program/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-rd-day/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/scientific-reports-publishes-inforaaa-results/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-11/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/juho-jalkanen-appointed-chief-operating-officer/</loc><lastmod>2025-01-29T15:42:05+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-7/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-at-proactive-one2one-investor-forum/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-redeye-fight-cancer-seminar/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-the-h-c-wainwright-bioconnect-virtual-conference/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-appoints-marie-louise-fjallskog-as-cmo/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-financial-calendar-for-2022/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-topline-matins-biomarker-analysis/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/change-in-farons-management-team/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-jefferies-conference-2021/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-awarded-eur-3-8-million-in-arbitration-case/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/cellular-and-molecular-life-sciences-publication/</loc><lastmod>2025-01-29T15:42:06+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-5/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/tr-1-standard-form-for-notification-of-major-holdings/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/registration-of-placing-shares-with-trade-register/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing-and-issue-price/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-issue-and-placing-of-shares-2/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/presentation-of-updated-matins-data-at-esmo/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-presentation-at-esmo-congress/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-the-virtual-h-c-wainwright-global-investor-conference/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/half-year-financials-january-1-june-30-2021/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-patient-dosed-in-phase-ii-iii-covid-19-trial/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-half-year-report/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-host-kol-webinar-on-the-potential-of-clever-1-receptor-as-a-target-for-macrophage-guided-immunotherapy-on-july-19-2021/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/updated-corporate-presentation/</loc><lastmod>2025-01-29T15:42:07+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-granted-key-us-patent/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-results-published-in-ccr/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-shows-promising-anti-tumour-activity/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/us-rights-to-patent-related-to-traumakine/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-12/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-8/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/board-change-3/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-agm/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/appointment-of-a-broker/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-6/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-faron-pharmaceuticals-ltds-agm-3/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-annual-report-2020-published/</loc><lastmod>2025-01-29T15:42:08+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/financial-statement-january-1-to-december-31-2020/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-clevegen-development-update/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-oppenheimer-conference/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-h-c-wainwright-conference/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-full-year-results-and-annual-report/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-the-company/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/registration-of-placing-shares/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing-and-issue-price-2/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-issue-and-placing-of-shares-3/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-traumakine-development/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-clevegen-development-update-2/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/us-department-of-defense-dod-to-support-traumakine-development/</loc><lastmod>2025-01-29T15:42:09+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-h-c-wainwright-bioconnect/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-financial-calendar-for-2021/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/presentations-at-esmo-immuno-oncology-virtual-congress-build-case-for-clever-1-as-a-new-immune-checkpoint-target/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-to-participate-in-upcoming-investor-conferences/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/bexmarilimab-clevegen-development-update-3/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-issue-of-equity/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-results-from-who-solidarity-trial/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-9/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/tr-1-s-tandard-form-for-notification-of-major-holdings/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-7/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/half-year-report/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-trial-data-presented-at-esmo/</loc><lastmod>2025-01-29T15:42:10+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-present-at-h-c-wainwright-conference-2/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-half-year-report-2/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-update/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/change-of-adviser/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/managers-transactions-3/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-hosts-virtual-rd-day-today/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-update-on-pipeline-progress-ahead-of-rd-day/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-receives-eur-2-1-million-funding-from-bf/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-selected-for-eur2-5-million-grant-from-eic/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-update/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-rd-day-to-be-held-in-june/</loc><lastmod>2025-01-29T15:42:11+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-oy-harmful-association-of-glucocorticoids-in-interferon-beta-1a-treated-patients-published-in-intensive-care-medicine/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-the-annual-general-meeting-2/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-options-8/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/managers-transactions-4/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-receives-grant-from-business-finland/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/clevegen-manufacturing-agreement/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-13/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-14/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-to-be-a-part-of-whos-solidarity-trial/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-results-of-placing-and-issue-of-equity/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-placing-and-issue-price/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-annual-general-meeting/</loc><lastmod>2025-01-29T15:42:12+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/agm-to-be-postponed/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/part-1-of-the-matins-phase-i-ii-study-completed/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/correction-to-farons-annual-report-2019/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-annual-report-2019-published/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-annual-general-meeting-2/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/final-results-for-the-year-ended-december-31-2019/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-accepts-protocol-for-new-traumakine-trial/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-update-2/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-to-acquire-aoc3-antagonist-platform/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-update-2/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/ovarian-cancer-selected-as-2nd-matins-trial-cohort/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/dmc-approves-colorectal-cancer-cohort-expansion/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-traumakine-drug-substance-manufacturing/</loc><lastmod>2025-01-29T15:42:13+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-trial-update/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/liquidity-providing-agreement/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/company-description-information-on-cash-position/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-has-approved-farons-clevegen-ind/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-financial-calendar-for-2020/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-15/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/application-to-nasdaq-first-north-growth-market/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/registration-of-shares/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing-and-issue-price-3/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing-and-financial-adviser-appointment/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/statement-regarding-price-movement/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-egm-3/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-trial-update-2/</loc><lastmod>2025-01-29T15:42:14+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-egm/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-traumakine-drug-substance-manufacturing-2/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-poster-presentation-at-esmo-congress/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-16/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/interim-results/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-study-selected-for-esmo-2019/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-open-offer-and-further-subscription/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-17/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-interim-results/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/issue-of-equity/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/subscription-and-open-offer/</loc><lastmod>2025-01-29T15:42:15+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-study-update/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-18/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-10/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/phase-ii-inforaaa-study-update/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/final-results-from-yoda-study/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-agm-2/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/agm-update-board-management-changes/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-11/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-19/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-20/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-21/</loc><lastmod>2025-01-29T15:42:16+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/share-subscription-and-issue-of-equity/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-agm/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/statement-regarding-price-movement-2/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-from-the-japanese-phase-iii-study/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-22/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-23/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-expansion-cohort-for-matins-trial-part-2/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-24/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-results/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-25/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-the-placing-and-subscription/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-placing-and-issue-price-2/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing-to-raise-approximately-eur-3m/</loc><lastmod>2025-01-29T15:42:17+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/matins-study-update-2/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/new-data-published-by-clinical-cancer-research/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-update-yoda-results/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-patient-dosed-in-phase-i-ii-matins-study/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-26/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/patient-subgroup-identified-from-interest-trial/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-receives-cta-approval-for-clevegen/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/pdmr-dealings/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/interest-trial-update-presented-at-esicm/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-cta-filing-for-clevegen/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/new-data-published-on-clever-1-function/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-27/</loc><lastmod>2025-01-29T15:42:18+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/clevegen-successful-toxicity-studies/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-28/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-2/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-3/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-29/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-30/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/biomarker-analysis-of-phase-iii-interest-trial/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-agm-2/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/agm-statement/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/pdmr-shareholding/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-4/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-31/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-32/</loc><lastmod>2025-01-29T15:42:19+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-33/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-34/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-the-phase-iii-interest-trial/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-agm-2/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-35/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/top-line-data-from-the-phase-iii-interest-trial/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/final-results-for-the-year-ended-31-december-2017/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-36/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-full-year-results/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-37/</loc><lastmod>2025-01-29T15:42:20+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-38/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-39/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-40/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-41/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-42/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/issue-of-equity-2/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-placing-issue-of-equity/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-hosts-rd-day-today-in-london/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing-to-raise-up-to-15m/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/second-traumakine-manufacturing-site-established/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-clevegen-grant-of-european-patent/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-grants-fast-track-designation-for-traumakine/</loc><lastmod>2025-01-29T15:42:21+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-approval-of-farons-traumakine-ind/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/inforaaa-trial-receives-recommendation-from-idmc/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-announces-rd-day-in-february-2018/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/recruitment-completed-in-traumakine-interest-trial/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-43/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-44/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/appointment-of-chief-commercial-officer/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-45/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-12/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/change-of-adviser-2/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-46/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-5/</loc><lastmod>2025-01-29T15:42:22+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/issue-of-equity-pdmr-shareholding/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-placing-subscription-issue-of-equity/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing-and-subscription/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/traumakine-receives-pim-designation-from-mhra/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/directors-dealings/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/interim-results-2/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/fda-advises-faron-to-proceed-directly-to-bla/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-interest-phase-iii-study-from-idmc/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-47/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-48/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-results-2/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-6/</loc><lastmod>2025-01-29T15:42:23+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-warrants-and-options/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-49/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-7/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-8/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-9/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-agm-3/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/update-on-interest-phase-iii-study-from-idmc-2/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/exercise-of-warrants/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/directors-dealings-2/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-10/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-board-changes/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-annual-general-meeting-3/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/purchase-of-shares/</loc><lastmod>2025-01-29T15:42:24+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/collaboration-with-birmingham-university/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/purchase-of-shares-2/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-pdmr-shareholding-11/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/final-results-2016/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-50/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-51/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-full-year-results-2/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-52/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/result-of-placing-subscription-issue-of-equity-2/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing-and-subscription-2/</loc><lastmod>2025-01-29T15:42:25+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-patient-recruited-in-phase-ii-raaa-study/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-update-for-2017/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notification-of-major-interest-in-shares/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notification-of-major-interest-in-shares-2/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/pdmr-shareholding-2/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/grant-of-options-13/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/new-application-accepted-by-finnish-patent-office/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-patient-recruited-in-japanese-ph-iii-trial/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notification-of-major-interest-in-shares-3/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notification-of-major-interest-in-shares-4/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notification-of-major-interest-in-shares-5/</loc><lastmod>2025-01-29T15:42:26+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/director-dealing/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/raises-8-0-m-through-a-placing-and-subscription/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-placing-subscription-to-raise-8m/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/interim-results-for-six-months-ended-30-june-2016/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-notice-of-interim-results/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-provides-update-at-rd-day/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-licenses-traumakine-rights-to-pharmbio-korea/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-result-of-annual-general-meeting/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-expands-rd-strategy-for-clevegen/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-ltd-to-host-an-rd-day/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-agm-3/</loc><lastmod>2025-01-29T15:42:27+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-appoints-new-medical-director/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-appoints-panmure-gordon-as-joint-broker/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-files-two-new-patents-to-protect-clevegen/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/annual-results-for-the-year-ended-31-december-2015/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-files-patent-application-for-traumakine/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-preliminary-results/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/top-line-results-from-japanese-study-of-traumakine/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/first-patient-recruited-in-phase-iii-ards-study/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-awarded-1-5-million-tekes-funding/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/key-publication-in-journal-of-immunology/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/admission-to-aim-and-first-day-of-dealings/</loc><lastmod>2025-01-29T15:42:28+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/final-patient-identified-for-the-bexmab-study/</loc><lastmod>2025-01-31T09:00:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/proposed-issue-and-placing-3/</loc><lastmod>2025-02-05T18:30:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/results-of-the-significantly-oversubscribed-placing/</loc><lastmod>2025-02-06T09:00:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-53/</loc><lastmod>2025-02-14T17:16:40+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/change-of-broker/</loc><lastmod>2025-02-11T09:30:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/holdings-in-company-54/</loc><lastmod>2025-02-14T17:16:36+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-will-publish-its-financial-statement-release-2024-and-annual-report-2024-on-thursday-27-february-2025/</loc><lastmod>2025-02-19T12:00:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/farons-financial-statement-release-1-january-to-31-december-2024/</loc><lastmod>2025-02-27T09:00:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/faron-pharmaceuticals-ltds-annual-report-2024-published/</loc><lastmod>2025-02-27T09:15:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/inside-information-faron-receives-positive-ema-opinion-on-orphan-drug-designation-for-bexmarilimab-for-the-treatment-of-myelodysplastic-syndrome-mds/</loc><lastmod>2025-02-27T09:30:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/notice-of-faron-pharmaceuticals-ltds-annual-general-meeting/</loc><lastmod>2025-02-28T14:00:00+02:00</lastmod></url><url><loc>https://faron.com/releases-and-publications/inside-information-fda-grants-orphan-drug-designation-for-bexmarilimab-in-mds/</loc><lastmod>2025-03-03T14:00:00+02:00</lastmod></url></urlset>
